Cardio Diagnostics CEO Reveals India Expansion and Medicare Progress on Podcast

In a recent episode of The BioMedWire Podcast, Cardio Diagnostics Holdings (NASDAQ: CDIO) CEO and Co-Founder Dr. Meesha Dogan shared the company's mission to revolutionize cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics, and artificial intelligence. Dogan detailed the company's expansion into India via strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs, marking a significant step in global reach. Additionally, she discussed progress in the Medicare reimbursement process, noting that CPT coding and payment steps are complete, though coverage determination is still pending. Cardio Diagnostics, an AI-powered precision cardiovascular medicine company, aims to make prevention, detection, and management of cardiovascular disease more accessible and personalized. The company leverages a proprietary AI-driven Integrated Genetic-Epigenetic Engine to develop clinical tests. For more details, the full press release is available at https://ibn.fm/0VjIz. The latest news and updates on CDIO can be found in the company's newsroom at https://ibn.fm/CDIO. Cardio Diagnostics' forward-looking statements include risks and uncertainties, as detailed in their SEC filings.

Cardio Diagnostics' focus on precision medicine represents a paradigm shift from traditional one-size-fits-all approaches to cardiovascular care. By integrating epigenetic and genetic data with AI, the company aims to identify individuals at risk earlier and tailor interventions more effectively. The India expansion via partnerships with established healthcare providers like Aimil Ltd. and Dr. Lal PathLabs demonstrates the scalability of their technology and addresses a critical need in a country with a high burden of cardiovascular disease. The Medicare reimbursement progress is equally crucial, as it paves the way for broader patient access and adoption in the U.S. healthcare system. Dr. Dogan's appearance on the BioMedWire Podcast underscores the company's commitment to transparency and education, engaging with investors and the medical community alike.